NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

PN in NF1 cause substantial morbidity. In a phase I trial of selumetinib, 17/24 patients had a partial response (PR). This study evaluates the PR rate of PN to selumetinib and changes in PN-related morbidities. Patients 2-18 years with NF1, inoperable PN and ≥ 1 PN-related morbidity received continu...

全面介紹

Na minha lista:
書目詳細資料
發表在:Neuro Oncol
Main Authors: Gross, Andrea, Wolters, Pamela, Baldwin, Andrea, Dombi, Eva, Fisher, Michael J, Weiss, Brian, Kim, AeRang, Blakeley, Jaishri, Whitcomb, Patricia, Holmblad, Marielle, Maritin, Staci, Roderick, Marie Claire, Paul, Scott M, Therrien, Janet, Heisey, Kara, Doyle, Austin, Smith, Malcolm, Glod, John, Steinberg, Seth, Widemann, Brigitte C
格式: Artigo
語言:Inglês
出版: Oxford University Press 2018
主題:
Abstracts
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.515
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍